Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.
Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P.
Int J Mol Sci. 2021 Sep 26;22(19):10372. doi: 10.3390/ijms221910372.
PMID:34638713
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J.
J Hepatol. 2021 May;74(5):1188-1199. doi: 10.1016/j.jhep.2020.11.045. Epub 2020 Dec 2.
PMID:33278455
GSDMD-Dependent Neutrophil Extracellular Traps Mediate Portal Vein Thrombosis and Associated Fibrosis in Cirrhosis.
Che Y, Chien Y, Zhu Y, Huang X, Wu L, Ai Y, Jiang S, Li F, Chen S.
Int J Mol Sci. 2024 Aug 22;25(16):9099. doi: 10.3390/ijms25169099.